Do you have a strategy for responding to the temperamental IPO market and making the most of alternative financing strategies?
Foley & Lardner LLP and the NanoBusiness Alliance are pleased to invite senior business executives and investors to participate in a roundtable discussion addressing how nanotechnology companies can develop financing strategies for success.
Discussion topics include:
- Financing growth and development of a nanotechnology company with long product development timelines, little or no near-term revenue, and potential applications in many industries
- Determining when the sale of your company is the most viable and what factors have made other nanotechnology companies attractive targets
- Deciding whether to go IPO, OTC, AIM, or private equity
- Exploring nontraditional financing options
- Positioning your company for the best financing options
Confirmed Boston Attendees:
Tim Cesarek, President, Koch Genesis Company, LLC
Mark Modzelewski, Vice President, NanoDynamics
Justin Hall-Tipping, Senior Managing Partner, NanoHoldings LLC
Scott Livingston, Managing Director, The Livingston Group, Axiom Capital Management Inc.
Curt Creely, Partner, Foley & Lardner LLP
People
Related Insights
July 17, 2025
Health Care Law Today
One Big Beautiful Bill: Slashed Budgets Will Disrupt the Medicaid Program
The new federal budget law, the One Big Beautiful Bill Act (the Act), enacted on July 4, 2025, makes dramatic changes to the Medicaid…
July 16, 2025
Foley Viewpoints
Changes to the College and University Endowment Tax
The One Big Beautiful Bill Act (OBBBA) modifies the excise tax on net investment income of private colleges and universities under…
July 16, 2025
Health Care Law Today Podcast
Episode 36: Let’s Talk Compliance: The Risks and Pitfalls of Health Care Supply Chain Compliance
In this episode, Monica Chmielewski, vice chair of Foley’s Health Care Practice Group and Shannon Sumner, Chief Compliance Officer and Nashville’s Office Managing Principal of PYA explore how supply chain compliance is affecting the health care industry and share the risks and penalties associated with not being in compliance.